Research progress in human metapneumovirus fusion protein vaccines
10.3760/cma.j.cn112309-20240429-00153
- VernacularTitle:人偏肺病毒融合蛋白疫苗研究进展
- Author:
Yidan WANG
1
;
Zhihua LI
;
Yanwei BI
;
Qianqian LI
Author Information
1. 中国医学科学院医学生物学研究所，病原体感染防控教育部重点实验室（北京协和医学院），昆明 650031
- Keywords:
Human metapneumovirus;
Vaccine;
Fusion protein;
Antigen design
- From:
Chinese Journal of Microbiology and Immunology
2024;44(7):608-613
- CountryChina
- Language:Chinese
-
Abstract:
Human metapneumovirus, first identified in the Netherlands in 2001, is a common respiratory virus belonging to the genus Metapneumovirus of the family Pneumoviridae. It has spread across the world. It can cause repeat infections in infants, young children, the elderly, and immunocompromised people, and lead to acute respiratory infections. There are currently no effective prophylactic vaccines approved for marketing. This article mainly focuses on the virological and epidemiological characteristics of human metapneumovirus, introduces the structure of fusion protein, a potential key immunogen for vaccine development, and the antigenic loci on fusion protein, and summarizes the research progress in subunit vaccines, live attenuated vaccines, and nucleic acid vaccines designed based on fusion protein.
